- Investing.com
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Metrics to compare | ABVC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABVCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.5x | −6.4x | −0.6x | |
PEG Ratio | −0.30 | −0.02 | 0.00 | |
Price/Book | 4.4x | 2.6x | 2.6x | |
Price / LTM Sales | 66.8x | 19.2x | 3.2x | |
Upside (Analyst Target) | - | 61.5% | 41.8% | |
Fair Value Upside | Unlock | −2.7% | 5.1% | Unlock |